

Differential regulation of 5-aminolevulinate synthase isozymes in vertebrates

Kazumichi Furuyama¹ and Masayuki Yamamoto²

¹Department of Molecular Biology and Applied Physiology

²Department of Biochemistry

Tohoku University Graduate School of Medicine

2-1 Seiryō-machi, Aoba-ku, Sendai, Miyagi 980-8575 Japan

Table of contents

- I. Introduction
- II. Biosynthetic pathway of heme in vertebrate
- III. Identification of 5-aminolevulinate synthase (ALAS) and tissue-specific regulation of heme biosynthesis
- IV. Establishment of ALAS isozymes
- V. Regulation of ALAS-N (ALAS1) expression
 - A. Heme is a powerful suppressor for ALAS-N expression
 - 1. Negative regulation of ALAS-N transcription and mRNA stability by heme
 - 2. Heme-mediated inhibition of ALAS-N translation
 - 3. Inhibition of mitochondrial translocation of ALAS-N by heme
 - 4. Heme-mediated degradation of ALAS-N protein in mitochondria
 - B. Xenobiotics-mediated induction of ALAS-N expression
 - C. Other regulators for ALAS-N expression
 - 1. Glucose metabolism and heme biosynthesis
 - 2. Circadian rhythm of heme biosynthesis
 - 3. Other transcription factors regulating ALAS-N expression
- VI. Expression and its regulation of ALAS-N in vivo
- VII. Regulation of ALAS-E (ALAS2) expression
 - A. Transcriptional regulation of ALAS-E gene (ALAS2)
 - 1. Identification of several erythroid specific cis acting elements in the proximal promoter region of mouse Alas2 gene
 - 2. Transcriptional regulation of human ALAS2 gene by its promoter
 - 3. Erythroid-specific enhancer in intron 8 for transcriptional regulation of ALAS2 gene
 - 4. Hypoxic upregulation of ALAS2 mRNA expression
 - B. Translational regulation of ALAS-E
 - 1. Intracellular iron regulates ALAS-E translation
 - 2. Heme-mediated translational regulation of ALAS-E
 - C. Post-translational regulation of ALAS-E protein
 - 1. Does heme inhibit translocation of ALAS-E into mitochondria?

2. Post-translational regulation through interaction with the other proteins
 3. Processing of ALAS-E protein in mitochondria
 4. Hypoxia stabilizes ALAS-E protein
- VIII. The role of ALAS-E in hematopoiesis in vitro
- A. Suppression of ALAS-E expression in murine cell line
 - B. In vitro differentiation of ALAS-E null ES cells
 - C. Heme-mediated regulation of expression of other genes
- IX. Essential role of ALAS-E in erythropoiesis and iron homeostasis in vivo
- A. Role of ALAS-E expression in zebrafish
 - B. Targeting disruption of ALAS-E gene in mice
 - C. Transgenic rescue of ALAS-E null mice
- X. Summary and perspectives for the future

I. Introduction

Heme plays an essential role in several biological pathways, such as hemoglobin formation, electron transfer in mitochondria and xenobiotic metabolism, as a prosthetic group of several proteins¹. On the other hand, excess amount of heme might produce reactive oxygen species; therefore heme production in mammalian cells is tightly regulated. In this chapter, it will be discussed how heme biosynthetic pathway is regulated in animal cells by focusing the regulatory mechanisms for the expression of 5-aminolevulinic acid synthase (ALAS), which is the first and rate-limiting enzyme of heme biosynthetic pathway.




Figure 1. Heme biosynthetic pathway in vertebrates (Adopted from ref. 1)

ALA, 5-Aminolevulinic acid; PBG, Porphobilinogen; HMB, Hydroxymethylbilane; URO III, Uroporphyrinogen III; COPRO III, Coproporphyrinogen III; PPG IX, Protoporphyrinogen IX; PP IX, Protoporphyrin IX; ALAS, 5-Aminolevulinic acid synthase; ALAD, 5-Aminolevulinic acid dehydratase; HMBS, Hydroxymethylbilane synthase (= PBGD: Porphobilinogen deaminase; UROS, Uroporphyrinogen III synthase; UROD, Uroporphyrinogen decarboxylase; CPOX, Coproporphyrinogen oxidase; PPOX, Protoporphyrinogen oxidase; FECH, ferrochelatase

II. Biosynthetic pathway of heme in vertebrate

Eight enzymes are involved in heme biosynthetic pathway in mammals². As shown in Figure 1, heme biosynthesis is initiated by ALAS, which condensates glycine and succinyl Coenzyme A (CoA) to form aminolevulinic acid (ALA). This reaction is catalyzed in mitochondrial matrix where ALAS is localized. Synthesized ALA is exported to cytoplasm; two molecules of ALA are then condensed to produce one molecule of porphobilinogen (PBG), which reaction is catalyzed by ALA dehydratase (ALAD). Then, hydroxymethylbilane synthase (HMBS) (alternatively, porphobilinogen deaminase; PBGD) linearize four molecules of PBG to form hydroxymethylbilane (HMB). HMB is subsequently circularized by uroporphyrinogen III synthase (UROS) to form uroporphyrinogen III (UROIII). Stepwise decarboxylation of UROIII by uroporphyrinogen decarboxylase (UROD) and coproporphyrinogen oxidase (CPOX), which is fifth and sixth enzyme, respectively, produce protoporphyrinogen IX. Protoporphyrinogen IX is then oxidized by protoporphyrinogen oxidase (PPOX) to form protoporphyrin IX (PPIX). As the last step of heme biosynthetic pathway, ferrochelatase (FECH) produce heme by chelating ferrous iron into the center of PPIX. Among of these eight enzymes, only ALAS have two distinct isozymes, each of which are encoded by independent gene, resulting in a differential regulation of heme biosynthesis in erythroid cells and non-erythroid cells.

III. Identification of 5-aminolevulinic synthase (ALAS) and tissue-specific regulation of heme biosynthesis

In 1958, Laver et al.³ demonstrated the enzymatic formation of 5-ALA using a certain particle fraction, which might be a mitochondria rich fraction, obtained from a lysate of avian erythrocytes. Using this system, Gibson et al. reported that this enzyme condensate glycine and succinyl-CoA to form ALA⁴. Kikuchi et al. independently succeeded the first purification of soluble ALAS from the extracts of *Rhodospseudomonas spheroides* and

*Rhodospirillum rubrum*⁵. Thereafter, as a source of ALAS, avian erythrocytes and photo-synthetic bacteria was preferentially used to examine the regulation of ALAS expression in vertebrates and to clarify the mechanisms of enzymatic reaction of ALAS, respectively. As for the regulation of heme biosynthetic pathway in mammals, Granick and Urata first showed the evidences that 3,5-dicarbethoxy-1,4-dihydrocollidine (DDC) induced ALAS activity in hepatocyte mitochondria isolated from Guinea pig⁶. Miyakoshi et al. also confirmed that allylisopropylacetamide (AIA) induced the ALA synthesis in rat liver mitochondria⁷.

It has been suggested that ALAS is the rate-limiting enzyme of heme biosynthetic pathway in liver⁶, as well as in erythroid cells⁸, however, Wada et al. reported that ALAS activity in hematopoietic tissue was differently regulated from that in liver⁹, when mice were treated with hypoxia or DDC. Briefly, ALAS activity in hematopoietic tissue (spleen), but not in liver, was increased under hypoxic environment, while ALAS activity was greatly induced only in liver by DDC treatment. Moreover, these authors found that hemin treatment could prevent the induction of ALAS activity in liver after DDC treatment, although there was no effect on the induction of ALAS activity in hematopoietic tissues under hypoxia. These results suggested that ALAS activity was independently regulated in hematopoietic tissues or in liver.

IV. Establishment of ALAS isozymes

Although ALAS activity was known to be differentially regulated in liver and in hematopoietic organs (fetal liver and adult bone marrow)^{9, 10}, it was not clear whether hepatic ALAS and erythroid one was identical or not. Bishop et al. demonstrated that some biochemical properties (e.g., binding affinity to AMP-agarose, Km value for glycine and the inhibition of enzymatic activity by 0.4M sodium chloride) were different between erythroid and non-erythroid ALAS, which were purified from hematopoietic organs and liver of guinea pig, respectively¹¹. Then, Watanabe et al. found that in vitro translated products using polysomes isolated from chicken

erythroid and hepatic cells showed different molecular size (estimated as 73 kDa or 55kDa, for each protein translated from liver polysomes or erythroid polysomes, respectively) based on SDS-PAGE analysis¹². Interestingly, these authors also found that molecular size of each mitochondrial enzymes purified from chicken erythrocyte or liver was different from those of polysome derived ALAS protein. Moreover, Ouchterlony double-diffusion study demonstrated that ALAS purified from chicken erythroid cells was only partially cross-reactive with the antibody against ALAS that was purified from chicken liver mitochondria¹². These results strongly suggested that ALAS expressed in hematopoietic tissues was not identical to that expressed in liver, and each ALAS was modified post-translationally during or after mitochondrial translocation.

Finally, molecular cloning of distinct cDNA was required to distinguish ALAS isozymes. ALAS cDNA for chicken¹³, mouse¹⁴ and human¹⁵ were cloned from liver cDNA library. Independently, screening of chicken erythroid cell cDNA library resulted in the isolation of erythroid-specific transcript¹⁶. However, some researchers still believed that single ALAS mRNA species was transcribed from unique gene in all tissues based on ubiquitous expression of hepatic ALAS cDNA^{14, 17, 18}. In 1989, Riddle et al. reported the molecular cloning of two independent chick ALAS cDNAs which encoded erythroid specific isozyme (named erythroid-specific ALAS; ALAS-E) or ubiquitously expressed isozyme (named non-specific ALAS; ALAS-N)¹⁹. Although each isozyme was encoded by distinct gene, predicted amino acid sequence of chicken ALAS-E protein was 57% identical to that of chicken ALAS-N in over all protein, and it was increased to more than 75% when their internal core region were compared¹⁹. Moreover, predicted molecular size of chick ALAS-E protein based on open reading frame (ORF) of erythroid ALAS cDNA was approximate 55 kDa¹⁹, which showed excellent agreement to the estimated molecular size of in vitro translated protein using polysome derived from chicken erythroid cells¹². Following this report, the expression of erythroid-specific ALAS mRNA in erythroid cells was established in mouse^{14, 20}, rat²¹ and human²². Mapping of genes for ALAS-N and ALAS-E was also performed, and the results

confirmed that ALAS-N and ALAS-E were encoded by distinct gene. ALAS-N protein and ALAS-E protein was encoded by ALAS1 gene and ALAS2 gene, respectively. ALAS1 and ALAS2 was mapped on chromosome 3 (3p21) and X chromosome (Xp11.21) for human²²⁻²⁴, or chromosome 9 (mouse genome informatics ID:87989) and X chromosome²⁵ for mouse, respectively.

V. Regulation of ALAS-N (ALAS1) expression

A. Heme is a powerful suppressor for ALAS-N expression

After the initial proposal by Granick in 1966²⁶, it has been demonstrated that heme strongly suppressed ALAS-N expression at several steps, including transcription, translation and post-translational modification (Figure 2). Hence, depletion of free heme pool (alternatively, regulatory heme pool), which may be caused by decreased de novo heme synthesis or unexpected consumption of excess amount of heme, is able to induce ALAS-N expression in non-erythroid cells.




Figure 2.

Negative feedback regulation of ALAS-N expression by heme

The figure summarizes the negative feedback regulation of ALAS1 expression by heme. Red bar with arrow indicates the suppression of each step. (Adopted from ref. 1)

1. Negative regulation of ALAS-N transcription and mRNA stability by heme

Yamamoto et al. found that intravenous administration of hemin to rats dose-dependently suppressed the *in vitro* translational ability of ALAS-N by polysomes isolated from liver, in which ALAS-N expression was induced by allylisopropylacetamide (AIA) pretreatment²⁷. Authors also found that the half-life of mRNA for ALAS-N in the polysome fraction was not shortened after hemin administration, suggesting that hemin could suppress ALAS-N expression at transcriptional level. Hemin-mediated transcriptional suppression of ALAS-N was also confirmed *in vivo* by measuring ALAS-N mRNA level and its half-life in rat liver, which was treated with AIA and inhibitors of transcription²⁸.

At least two independent mechanisms might involve in this heme-mediated transcriptional repression of ALAS-N. It has been reported that orphan nuclear receptor Rev-*arba* act as a heme sensor²⁹, and heme binding to it recruited NCoR/histone deacetylase 3 (HDAC3) corepressor complex, which repressed the transcription of peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1 α)³⁰. Since PGC-1 α regulates ALAS-N transcription positively³¹, heme binding to Rev-*arba* resulted in the reduction of ALAS-N transcription³².

Gotoh et al.³³ proposed another mechanism. These authors reported the identification of heme-responsive element (HRE) in the proximal promoter region of mouse ALAS-N gene, as well as the combinatorial binding of early growth response 1 (Egr-1) and its corepressors (NBA1 and NBA2) to HRE. The interaction of Egr-1 and corepressors was strengthened by higher concentration of intracellular heme, thereby suppressing ALAS-N transcription. It is thus possible that both mechanisms synergistically regulate heme-mediated transcriptional repression of ALAS-N gene.

As for the effect of hemin on ALAS-N mRNA stability, Drew and Ades reported that hemin destabilized ALAS-N mRNA in chick embryo hepatocyte *in vitro*³⁴. Hamilton et al. also examined the effect of hemin on the half-life of ALAS-N mRNA in chick embryo hepatocyte *in vitro*, and found that heme decreased ALAS-N mRNA stability, while such effect was

prevented by the treatment with certain inhibitor for translation, such as cycloheximide³⁵. These results suggested that heme involved in the destabilization of ALAS-N mRNA by enhancing the synthesis of a labile protein. Similar negative effect of heme on ALAS-1 mRNA stability was also observed in rat cell line³⁶. Moreover, Roberts et al. found that alternative splicing of human ALAS-N gene produced longer transcript at its 5'UTR, and such longer transcript was resistant to heme-mediated ALAS-N mRNA decay³⁷. These authors also suggested that de novo translated proteins from this extended 5'-UTR of ALAS-N mRNA may be involved in the stabilization of this longer transcript³⁷. However, such protein that involves in the stabilization of ALAS-N mRNA has not yet been identified to date.

2. Heme-mediated inhibition of ALAS-N translation

Effect of heme on the translation of ALAS-N protein has been reported by Sassa and Granick using in vitro culture of chick embryo liver cells³⁸. In this paper, authors found that the induction of ALAS activity in these cells by AIA or γ -hexachloro-cyclohexane was primarily mediated at translational level, and it was suppressed by the treatment with hemin. Furthermore, Yamamoto et al. examined the effect of hemin on the translation of ALAS-N using polysomes isolated from rat liver in combination with in vitro translation system³⁹. Proteins were labeled with radioisotope during in vitro translation, and synthesized ALAS-N protein was specifically immune precipitated using anti-ALAS-N antibody to determine the translational efficiency. As a result, authors found that synthesis of ALAS-N protein was reduced to about 40% of the control by 30 μ M hemin, whereas efficiency of total protein synthesis was not affected³⁹. However, molecular mechanism for this regulation still remains unclear.

3. Inhibition of mitochondrial translocation of ALAS-N by heme

It has been confirmed that ALAS-N was localized at mitochondrial matrix^{40, 41}, although ALAS-N is a nuclear encoded mitochondrial enzyme²². ALAS-N protein thus must be translated in cytosol as a precursor protein, and then transported into mitochondrial matrix to exhibit its function. As

discuss below, it has been well known that heme inhibits the translocation of ALAS-N protein into mitochondria, thereby suppresses ALAS activity. Since succinyl CoA, an essential substrate for ALAS, is exclusively available in mitochondrial matrix, ALAS is not able to produce ALA in cytosol. However, mechanisms for mitochondrial targeting of ALAS and its regulation by heme were unknown for a long time.

Sholnick et al. have first reported a partial purification of ALAS from soluble cytosol fraction of normal or AIA-treated rat liver⁴². Either enzyme purified from normal or AIA-treated rat was enzymatically active in vitro, while ALAS activity in soluble fraction increased approximate ten times after AIA-treatment. Since it was found that AIA-treatment induced the accumulation of ALAS in cytosol, as well as in mitochondria, authors hypothesized that ALAS might translocate from cytosol into mitochondria. Interestingly, using partially purified ALAS, these authors demonstrated that heme could directly inhibit ALAS activity in vitro in dose dependent manner, although the mechanism of such direct effect of heme on ALAS activity was unclear.

Hayashi et al. also found that the AIA-treatment on rat induced the accumulation of ALAS in soluble fraction of the liver, as well as in mitochondria⁴³. They have successfully purified ALAS from soluble fraction of the liver, and confirmed that such enzyme was active in vitro. It was also found that AIA-treatment mediated accumulation of ALAS protein in cytosol and mitochondrial fraction was abolished by the concurrent treatment with cycloheximide, mitomycin C, actinomycin D or hemin. Based on these results, authors hypothesized that ALAS was synthesized in cytosol, then subsequently translocated into mitochondria. Authors also found that the half-life of each protein and the suitable condition for ammonium sulfate fractionation for purification was different between cytosolic enzyme and mitochondrial enzyme, suggesting that mitochondrial ALAS was modified before or after entering the mitochondria. These authors also demonstrated that the administration of hemin into AIA-pretreated rat induced the accumulation of ALAS in cytosolic fraction of the liver, where as mitochondrial ALAS activity was greatly suppressed⁴⁴. Immunochemical

analysis revealed that specific antibody against the cytosolic enzyme similarly reacted to the mitochondrial one⁴⁵. Thus, the line of evidence suggested that cytosolic ALAS in liver should be a precursor form of mitochondrial ALAS.

Yamauchi et al. finally demonstrated that newly synthesized ALAS protein in cytosol was rapidly incorporated into mitochondria, and hemin could inhibit this step in the liver of AIA-treated rat⁴⁶. Interestingly, it was found that molecular size of newly synthesized ALAS subunit in vitro using polysomes isolated from rat liver was similar to that of ALAS purified from rat cytosol fraction, but significantly larger than that of ALAS purified from rat mitochondrial fraction⁴⁷. Since the difference in the subunit molecular size between cytosolic ALAS and mitochondrial ALAS was reproducibly observed in chicken liver¹², authors hypothesized that ALAS was translated as a precursor form in cytosol, then was processed in the course of translocation into mitochondrial matrix to become mature form. Hayashi et al. confirmed it using in vitro translation and translocation system⁴⁸. Briefly, radio-labeled precursor form of chicken ALAS-N was translated in vitro from chicken liver ribosomes, then translated proteins were incubated with purified chicken liver mitochondria. After the incubation, samples were centrifuged for separating mitochondrial fraction and supernatant to purify ALAS-N protein from each fraction by immunoprecipitation using anti ALAS-N antibody. After the purification of ALAS-N protein from each fraction, samples were analyzed by SDS-PAGE followed by autoradiography. As a result, in the mitochondrial fraction, precursor form and the mature form of ALAS-N protein was observed, latter of which was not detected in the supernatant. Authors also found that hemin could inhibit the mitochondrial translocation even in this cell-free system, suggesting that hemin might directly regulate this process.

Hemin-mediated accumulation of ALAS in liver cytosol was observed in several species, including rat (see above) and chicken⁴⁹, however, details of the mechanism for this regulation remained unknown until the excellent report by Lathrop and Timko⁵⁰. In this report, authors identified that amino (N-) terminal region of mouse ALAS-E worked as a presequence

for mitochondrial targeting and translocation into matrix. Although amino acid sequence of presequence was only 24% identical between ALAS-N and ALAS-E, authors found that a part of presequence were conserved between ALAS-E and ALAS-N presequence in human, chicken and mouse, and termed heme regulatory motif (HRM) (Figure 3). Consensus amino acid sequence of HRM consists of four peptides (Arg, Lys or Asn-Cys-Pro-Lys, Leu, Met or hydrophobic residue), whereas Cys-Pro dipeptides motif seemed to be a core sequence of HRM. Importantly, *in vitro* transcription, translation and mitochondrial import experiment revealed that these motives are responsible for the heme-mediated inhibition of mitochondrial translocation of mouse ALAS-E protein *in vitro*. Briefly, authors identified two distinct HRMs within the presequence of mouse ALAS-E, and disruption of both HRMs by replacing cysteine residue with serine residue released mouse ALAS-E protein from the heme-mediated inhibition of translocation. Of note, mitochondrial translocation of human ornithine transcarbamoylase (OTC), which was originally unregulated mitochondrial protein, was clearly inhibited by heme *in vitro*, when single HRM was inserted into OTC presequence. Thus, authors concluded that not only ALAS-E but also ANAS-N should be regulated their translocation from cytosol to mitochondrial matrix through HRM by heme.

In fact, Munakata et al. expressed the precursor protein for rat ALAS-N in Quail fibroblast, and observed that the mitochondrial translocation of rat ALAS-N was clearly inhibited by exogenous heme, although such heme-mediated inhibition was reversed by the introduction of the mutations, which replaced cysteine residue with alanine, into all three HRMs. These results indicated that HRMs of rat ALAS-N were responsible for the heme-mediated inhibition of mitochondrial translocation *in vivo*⁵¹. These authors also demonstrated that the mitochondrial translocation of ALAS-E was not inhibited by exogenous heme, suggesting that the expression of ALAS-E is only roughly regulated at this step by heme, compared to ALAS-N.




Figure 3. Amino acid sequence of human, mouse, rat and chicken ALAS at their N-terminal end.

Identical amino acid to that of human ALAS-N was shown as dot, and they were boxed. Lack of identical or similar amino acid to corresponding sequence of the other proteins was shown as “-”. Red horizontal bar indicates heme regulatory motif (HRM).

Dailey et al. also confirmed the biological consequence of HRMs in the presequence of human ALAS-N⁵². Similar to mouse and rat ALAS-N, there are three HRMs were identified in human ALAS-N, one of which was located at the N-terminal end of mature protein, and the other two were located within the presequence. Authors expressed N-terminal portion of human ALAS-N, which contained all putative HRMs, as a fusion protein with green fluorescent protein (GFP) in murine hepatoma cell line. Under the basal condition, targeting of GFP to mitochondria was not observed, suggesting that human ALAS-N presequence was sensitive to intracellular heme level in these cells, which might allow minimum amount of ALAS-N for targeting to mitochondria.

4. Heme-mediated degradation of ALAS-N protein in mitochondria

Heme-mediated protein degradation of ALAS-N in mitochondrial matrix was reported in rat hepatocyte⁵³, although its precise mechanism remained unknown. Using human liver cells, Tian et al. showed the evidences that lon peptidase 1 (LONP1), which was a nuclear encoded mitochondrial protease, involved in the degradation of mature ALAS-N protein in mitochondria. Moreover, authors demonstrated that the degradation of mature ALAS-N was accelerated by the increase of intracellular heme level, while suppression of LONP1 expression by specific siRNA diminished heme-dependent acceleration of ALAS-N degradation⁵⁴. However, the detail is still unclear how heme regulates the LONP1 protein expression.

B. Xenobiotic-mediated induction of ALAS-N expression

During an acute attack, a large amount of ALA and PBG was excreted in urine from patients with acute porphyria⁵⁵, and the induction of ALAS in the liver was responsible to this disease⁵⁶. Since a lot of medical

reagents induced ALAS expression in patient's liver², several chemical reagents, such as Sedormid⁵⁷, DDC^{26, 58}, hexachlorobenzene⁵⁹ or AIA^{26, 60, 61} were examined to induce the accumulation of ALA in animal body, to establish an animal model for acute porphyria. Especially, ALA was found to be greatly accumulated along with strong hepatic ALAS induction in guinea pig liver⁶ or rat liver⁷ by DDC or AIA treatment, respectively, these reagents were thus widely used to examine the mechanisms for ALAS1 induction in animal liver. Mechanisms for an induction of ALAS1 by these reagents have long been discussed, and it was found that their function was related to the interaction-based inactivation of cytochrome P-450 followed by the decrease of free heme pool^{62, 63}. Briefly, DDC interact with an active site of cytochrome P-450, resulting in an alkylation of pyrrole nitrogen atom of the heme moiety of cytochrome P-450. An alkylated heme loses its iron atom, thereby forming N-methyl protoporphyrin (N-methylPP). Since N-methylPP is a potent inhibitor of ferrochelatase, the last enzyme of heme biosynthetic pathway, formation of N-methylPP reduces heme supply to the free heme pool. AIA also alkylates nitrogen atom of heme moiety of cytochrome P-450, however, AIA covalently binds to the alkylated heme, and dissociates it from cytochrome P-450. Then, apo-P-450 combines with free heme to reconstitute P-450, resulting in the reduction of free heme pool. Thus, famous porphyrinogenic reagents, such as DDC and AIA, may indirectly induce ALAS-N expression in chicken, mouse or rat, through the feedback regulation triggered by the depletion of free heme pool.

As discussed above, proximal region of rat ANAS-N promoter plays a critical role for transcriptional regulation by hemin. However, Podvinec et al. pointed out that proximal promoter region of human ALAS-N gene was not responsible for the induction of ALAS-N promoter activity in Leghorn male hepatoma (LMH) cells by xenobiotics, such as phenobarbital, rifampicin or propylisopropylacetamide⁶⁴. These authors performed *in silico* analysis and identified putative enhancer elements for xenobiotic-mediated induction at 20 kbp and 16 kbp upstream of the transcription initiation site. It was shown that these enhancer regions directly responded to prototypic inducers, and interacted with human pregnane X receptor (PXR) and human

constitutive androstane receptor (CAR), both of which were known as an orphan nuclear receptor involved in drug-induced expression of cytochrome P450 (CYP). Thus, coordinated regulation of ALAS1 and CYPs in liver by several inducers could be explained well by this mechanism. These authors also proposed similar mechanism for drug-induced induction of ALAS-N expression in chicken⁶⁵ and mouse⁶⁶. Knockout study of PXR or CAR provided further evidences of the involvement of these molecules in the regulation of ALAS1 expression. Namely, PXR-null mice showed decreased response of ALAS1 mRNA induction in liver against xenobiotics treatment, whereas ablation of CAR gene resulted in decreased basal expression level of ALAS1 mRNA, but retained its inducibility against stimulation by xenobiotics⁶⁷. These results suggested that several mechanisms are involved in the drug-induced upregulation of ALAS1 gene.

C. Other regulators for ALAS-N expression

1. Glucose metabolism and heme biosynthesis

Blood sugar was maintained at certain level in healthy person by a consequence of insulin and glucagon action. Food intake increases blood sugar level that stimulates insulin secretion, and the fasting induced glucagon secretion. It has been reported that fasting is a precipitating factor for acute attack of acute intermittent porphyria (AIP), and urinary excretion of PBG of patient with AIP was reciprocally related to the intake of carbohydrate⁶⁸. Thus, large amount of glucose administration has been recognized as a useful treatment for acute attack of AIP². Tschudy et al. found that carbohydrate administration suppressed ALAS activity, which was induced by AIA treatment, in rat liver⁶⁹. Giger and Meyer presented the evidences that ALAS expression in the liver was induced by glucagon and cyclic AMP (cAMP), suggesting that expression level of ALAS was at least partially regulated by intracellular cAMP level in rat liver⁷⁰. Since molecular cloning of rat ALAS-N gene revealed the presence of several

consensus cis elements for transcription factors, such as NRF-1, NF- κ B and GATA, in rat ALAS-N proximal promoter region^{71, 72}, several researchers have tried to identify the responsible region for this “glucose effect” in the promoter. Scassa et al. revealed that the regulatory region for response to insulin was located between -459 and -354 in rat ALAS-N promoter, which contained cis elements for nuclear factor 1 (NF-1) and hepatic nuclear factor 3 (HNF-3)⁷³. Interestingly, these authors found that the region highly homologous to insulin responsive element (IRE), which was identified in the promoter of several genes repressed by insulin⁷⁴, was located between two distinct HNF-3 sites of rat ALAS-N promoter.

It has been known that peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1 α) induces the expression of many gluconeogenic key molecules, such as phosphoenolpyruvate carboxykinase and glucose-6-phosphatase, under fasting condition⁷⁵. It was also reported that the transcription of PGC-1 α was upregulated by binding of cyclic AMP response element (CRE) binding protein (CREB) to PGC-1 α promoter under glucose deprivation⁷⁶. Handschin et al.³¹ examined a role of PGC-1 α on ALAS-N expression, and found that the expression of ALAS-N and PGC-1 α in mouse liver was concomitantly regulated in fasting and feeding, and the forced expression of PGC-1 α induced ALAS-N expression in hepatocyte by recruiting FOXO1 and NRF-1 to IRE and NRF-1 binding site, respectively. PGC-1 α related induction of ALAS-N mRNA was repressed by insulin, which disrupting the interaction of PGC-1 α and FOXO1 by phosphorylation of FOXO1³¹. Finally, these authors also found that ALAS-N induction by fasting was not observed in liver-specific PGC-1 α knockout mice, suggesting the essential role of PGC-1 α in the regulation of ALAS-N expression in fasting condition. Thus, it was speculated that PGC-1 α expression was upregulated in the liver as a consequence of glucagon action in fasting condition, and PGC-1 α induced the ALAS-N transcription, thereby causing acute attack in patients with AIP. In contrary, administration of glucose increased the secretion of insulin, which inhibited the fasting-mediated induction of ALAS-N expression by reducing PGC-1 α expression, as well as

inhibiting the interaction of FOXO1 with PGC-1 α at IRE in ALAS-N promoter.

2. Circadian rhythm of heme biosynthesis

Zheng et al. first documented a circadian oscillation of ALAS-N mRNA expression in mice, which was regulated by mPer clock genes⁷⁷. Moreover, Yin et al reported the involvement of Rev-erba in the circadian regulation of ALAS-N expression²⁹. As discussed above, Rev-erba is able to bind to heme, resulting in the reduction of ALAS-N expression²⁹. It has been reported that Rev-erb β , which was structurally related to Rev-erba, was also heme ligand⁷⁸. Since both Rev-erba and Rev-erb β are critical components of mammalian clock, ALAS-N expression oscillates in a circadian manner⁷⁹. It was reported that binding of heme to Rev-erbs recruited corepressor NcoR to its binding site, thereby suppressed the target genes⁷⁸, including several key molecules for glucose metabolism, lipid metabolism, myogenesis and adipogenesis⁷⁹. Thus, heme should be widely involved in the regulation of metabolism and circadian clock.

3. Other transcription factors regulating ALAS-N expression

Giono et al. reported that there are two CRE like sites in the proximal promoter region of rat ALAS-N gene, and provided the evidences for direct binding of CREB to these CRE like sites⁸⁰. These CRE like sites were essential for cAMP dependent protein kinase (PKA)-induced regulation of ALAS-N promoter activity, authors thus concluded that CREB mediated the PKA based regulation of ALAS-N expression. Since these CRE like sites were located at -38 (proximal) and -142 bp (distal) of rat ALAS-N promoter, CREB might directly regulate ALAS-N expression, in addition to the indirect activation of ALAS-N gene through the induction of PGC-1 α , which was discussed above.

Guberman et al. reported that AP-1 family proteins, which expression was induced by 12-*O*-tetradecanoylphorbol-13-acetate (TPA), could bind to rat ALAS-N promoter region at -261 and -255 bp from transcription initiation site, thereby suppressed rat ALAS-N promoter

activity⁸¹. Moreover these authors provided evidences that this region played an important role for several signaling pathways mediated by PKC, phosphatidylinositol 3-kinase (PI3K), extracellular-signal regulated kinase (ERK1/2), and c-Jun N-terminal kinase (JNK)⁸².

Furthermore, two nuclear respiratory factor 1 (NRF-1) binding site has been identified at -58 and -88 bp of rat ALAS-N promoter, and functional consequence of these cis elements was determined⁷¹. As a result, disruption of one of each NRF-1 binding site decreased ALAS-N promoter activity and disruption of both sites diminished promoter activity completely. Thus, these NRF-1 binding sites play an essential role for maintaining the basal transcriptional level of ANAS-N gene.

VI. Expression and its regulation of ALAS-N in vivo

Although ALAS-N ubiquitously expresses in all tissues including erythroid tissues, its expression level is somewhat vary. For example, Srivastava et al. found that the highest expression of ALAS-N mRNA was observed in adrenal grand, and an approximate 50% of adrenal grand expression level was observed in small intestine, lung, heart and testis at the steady state level. As for in liver and kidney, only quarter of ALAS-N mRNA level in adrenal grand was detected⁸³. Although a crucial role of ALAS-N expression has been expected in the context of an essential role of heme in several organisms, it has never been examined in vivo until establishment of ALAS-N targeting mouse by Okano et al⁸⁴. This mice line was created by replacing the second exon of mouse *Alas1* gene with green fluorescent protein (GFP) expression cassette. Although authors found that heterozygous mice were viable and fertile, homozygous knock out mice (ANAS-N-null mice) were severely retarded in utero at embryonic day 6.5 (E6.5) and were completely reabsorbed by E8.5, demonstrating that ALAS-N is indispensable for the early embryogenesis of mouse⁸⁴.

Since second exon of *Alas1* gene contained translation initiation site for ALAS-N, and GFP expression cassette carried an original translation initiation site and poly adenylation signal for expression of GFP, GFP